311nm ultraviolet B-accelerated response of psoriatic lesions in adalimumab-treated patients

Photodermatology Photoimmunology and Photomedicine

Volumn 27, Issue 4, 2011, Pages 186-189

  Wolf, Peter ^a   Hofer, Angelika ^a   Weger, Wolfgang ^a   Posch Fabian, Timea ^a   Gruber Wackernagel, Alexandra ^a   Legat, Franz J ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

311nm; Adalimumab; Combination therapy; Psoriasis; Ultraviolet

Indexed keywords

ADALIMUMAB; ALEFACEPT; ETANERCEPT; ETRETIN; FUMARIC ACID; INFLIXIMAB; METHOTREXATE; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BODY REGIONS; CASE REPORT; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; MALE; PRIORITY JOURNAL; PSORIASIS; PUVA; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; ULTRAVIOLET B RADIATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PHOTOTHERAPY; REMISSION; ULTRAVIOLET RADIATION;

AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; REMISSION INDUCTION; ULTRAVIOLET RAYS; ULTRAVIOLET THERAPY;

EID: 79959982916     PISSN: 09054383     EISSN: 16000781     Source Type: Journal    
DOI: 10.1111/j.1600-0781.2011.00594.x     Document Type: Article

References (14)

1. Wolf P, Hofer A, Legat FJ, et al. Treatment with 311-nm ultraviolet B accelerates and improves the clearance of psoriatic lesions in patients treated with etanercept. Br J Dermatol 2009; 160: 186-189.
2. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006; 55: 598-606.
3. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-115.
4. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2007; 158: 558-566.
5. Papoutsaki M, Chimenti MS, Costanzo A, et al. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics. J Am Acad Dermatol 2007; 57: 269-275.
6. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23 (Suppl 2): 1-70.
7. Legat FJ, Hofer A, Wackernagel A, et al. Narrowband UV-B phototherapy, alefacept, and clearance of psoriasis. Arch Dermatol 2007; 143: 1016-1022.
8. Ortonne JP, Khemis A, Koo JY, Choi J. An open-label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2005; 19: 556-563.
9. Kircik LH, Liu C, Goffe BS. Treatment of moderate to severe plaque psoriasis with concomitant efalizumab and narrow-band ultraviolet B phototherapy. J Drugs Dermatol 2008; 7: 947-952.
10. Zane C, Capezzera R, Venturini M, et al. A short cycle of narrow-band UVB phototherapy in the early phase of long-term efalizumab can provide a quicker remission of moderate and severe psoriasis: a pilot study. Dermatology 2009; 218: 321-326.
11. Kircik L, Bagel J, Korman N, et al. Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes. J Drugs Dermatol 2008; 7: 245-253.
12. Hofer A, Fink-Puches R, Kerl H, Wolf P. Comparison of phototherapy with near vs. far erythemogenic doses of narrow-band ultraviolet B in patients with psoriasis. Br J Dermatol 1998; 138: 96-100.
13. Hearn RM, Kerr AC, Rahim KF, Ferguson J, Dawe RS. Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy. Br J Dermatol 2008; 159: 931-935.
14. Patel RV, Clark LN, Lebwohl M, Weinberg JM. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol 2009; 60: 1001-1017.